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Abstract The mechanisms by which urinary trypsin inhibitor 
(UTI) prevents preterm premature rupture of fetal membrane 
and premature cervical ripening were investigated. We, therefore, 
examined the effects of UTI on the production of matrix 
metalloproteinases (MMPs) which closely participate in the 
breakdown of extracellular matrix in cultured human uterine 
cervical fibroblasts and human chorionic cells. UTI suppressed 
specifically the production of interstitial procollagenase/ 
proMMP-1 and prostromelysin l/proMMP-3 from both cells 
in a dose-dependent manner (0.32-1.28 uM). This suppression 
was accompanied by a decrease in steady-state levels of their 
mRNAs. These results indicate for the first time that UTI down-
regulates the production of proMMP-1 and proMMP-3 
accompanying with the decrease in the expression of their 
mRNAs, and therefore UTI actually participates in the 
maintenance of fetal membranes and/or uterine cervix by overall 
suppression of MMP production along with the known inhibitory 
actions towards serine proteinases. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The uterine cervix and fetal membrane are typical connec-
tive tissues consisting of type I and III collagens and proteo-
glycans, and their tensile strength and/or toughness are con-
sidered to be maintained by extracellular matrices in those 
tissues. Thus abnormal advance in the breakdown of extra-
cellular matrix may lead the preterm premature rupture of 
fetal membrane (preterm PROM) and/or premature cervical 
ripening which lead to preterm labor [1-3]. The breakdown of 
extracellular matrix components is mainly accomplished by 
matrix metalloproteinases (MMPs) ([4] for review). In general, 
most connective tissue cells produce precursor forms of 
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MMPs (proMMPs) together with their endogenous inhibitors 
of TIMPs, and then proMMPs are activated by some protein-
ases such as plasmin [4]. TIMPs inhibit the activities of MMPs 
through the formation of 1:1 stoichiometrical complex with 
activated MMPs [4]. Thus the balance between MMPs and 
TIMPs is important in maintaining or breaking down the 
extracellular matrix. The production of proMMPs and TIMPs 
is regulated by various cytokines, growth factors and hor-
mones, and their production is finely timed in normal partu-
rition [4-7]. 
Urinary trypsin inhibitor (UTI), an acid-stable glycoprotein 
with a molecular mass of 67 kDa which is a light chain of 
inter-a trypsin inhibitor in plasma, is one of the Kunitz-type 
proteinase inhibitors [8,9]. The glycoside chains of UTI are 
composed of chondroitin-sulfate, and UTI is therefore char-
acterized as one of proteoglycans [10,11]. UTI inhibits the 
serine proteinases including trypsin, chymotrypsin, neutrophil 
elastase, cathepsin G and plasmin [8]. UTI is found in human 
amniotic fluid as well as human urine, and the level of UTI in 
amniotic fluid decreases in patients with PROM as compared 
with normal pregnancy [12]. Recently it was reported that 
UTI inhibits the production of interleukin 8 (IL-8) in macro-
phages [13] and the contraction of uterine muscle by modify-
ing the intracellular Ca2+ concentration [14]. Furthermore, 
UTI is known to prevent the preterm PROM [15], preeclamp-
sia [16], premature cervical ripening in rabbit [17] and preterm 
delivery in mouse [18]. These observations suggest that UTI 
might closely participate in the production and/or regulation 
of MMPs in fetal membrane and uterine cervix. 
In this report, we have investigated the effect of UTI on the 
production of MMPs and TIMPs in human uterine cervical 
fibroblasts and chorionic cells, and demonstrated that UTI 
suppresses specifically the production of proMMP-1/intersti-
tial procollagenase and proMMP-3/prostromelysin 1 accom-
panying the decrease in the expression of their mRNAs. 
2. Materials and methods 
2.1. Materials 
The following reagents were obtained commercially: Eagle's mini-
mum essential medium (MEM) and Dulbecco's modified Eagle's me-
dium/Ham's F12 mixed (1:1) medium (DMEM-Ham's F12) from Life 
Technologies, Inc., Grand Island, NY; fetal bovine serum (FBS) from 
Whittaker Bioproducts, Walkersville, MD; alkaline phosphatase-con-
jugated donkey anti-(sheep IgG)IgG from Sigma Chemical Co., St. 
Louis, MO; human glyceroaldehyde 3-phosphate dehydrogenase 
(GAPDH) cDNA probe from Clontech Laboratories, Inc., Palo 
Alto, CA. Sheep anti-(human proMMP-l)antiserum, sheep anti-(hu-
man MMP-3)antiserum, sheep anti-(human TIMP-l)antiserum, hu-
man MMP-1 cDNA (1.6 kb) and human MMP-3 cDNA (1.4 kb) 
were kindly provided by Prof. H. Nagase of the University of Kansas 
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Medical Center, Kansas City, KS. Recombinant human IL-la (IL-
l a ; 2X107 units/mg) was a kind gift from Dainippon Pharmaceutical 
Co., Suita, Osaka, Japan. Urinary trypsin inhibitor (UTI; 2330 units/ 
mg, 1 unit is defined as the amount of UTI for 50% inhibition of 2 itg 
of trypsin) was kindly provided by Mochida Pharmaceutical Co., 
Tokyo, Japan. Other reagents used were of analytical reagent grade. 
2.2. Cell cultures 
Human uterine cervical fibroblasts were prepared and maintained in 
MEM containing 10% (v/v) FBS as described previously [19]. In all 
experiments, cells up to the 6th passage were used. 
Human trophoblast-like cells (chorionic cells) prepared from cho-
rion leave were kindly provided by Dr. K. Ohyama, Second Depart-
ment of Biochemistry, Tokyo University of Pharmacy and Life Sci-
ence, and maintained in DMEM-Ham's F12 containing 20% (v/v) 
FBS. In all experiments, cells up to the 5th passage were used. 
For most of the experiments, confluent cells in 24-multiwell plates 
were washed once with calcium and magnesium-free phosphate buff-
ered saline [PBS(-)] and incubated with the serum-free respective me-
dium/0.2% (w/v) lactalbumin hydrolysate (LAH) containing IL—la 
and/or UTI for 24 h. The conditioned culture media were harvested 
and stored at —20°C until use. All experiments were conducted at 
least triplicate and typical data are presented. 
2.3. Western blot analysis 
Each culture medium (1 ml) from triplicate wells was mixed with 1/5 
volume of 20% (w/v) trichloroacetic acid. The resultant precipitates 
dissolved in reducing sample buffer of sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE) [20], were first subjected 
to SDS-PAGE with 10%) (w/v) acrylamide gel under reducing condi-
tions, and then proteins in the gel were electro-transferred onto a 
nitrocellulose membrane. The membrane was reacted with sheep 
anti-(human proMMP-l)antiserum, sheep anti-(human MMP-3)anti-
serum or sheep anti-(human TIMP-l)antiserum which was then com-
plexed with alkaline phosphatase-conjugated donkey anti-(sheep 
IgG)IgG. Immunoreactive proMMP-1, proMMP-3 and TIMP-1 
were visualized indirectly with 5-bromo-4-chloro-3-indolyl phosphate 
and Nitro Blue Tetrazolium as described previously [21]. 
2.4. RNA extraction and Northern blot analysis 
Confluent human uterine cervical cells or human chorionic cells in 
100 mm diameter dishes were treated with 15 ml of each medium/0.2%) 
(w/v) LAH containing IL-la and/or UTI. After 24 h of treatment, 
total cytoplasmic RNA was extracted with Isogen (Nippon Gene Co., 
Toyama, Japan) according to the manufacturer's instructions. Then 
extracted RNA (10 ug) was denatured with formamide and formal-
dehyde, electrophoresed to 1% (w/v) agarose containing 1 X 3-(7V-Mor-
pholino)propanesulfonic acid (MOPS) and 2.2 M formaldehyde, and 
transferred onto a nylon membrane (Gene Screen; DuPont, Boston, 
MA) in 10 X standard saline citrate (SSC). The membrane was hybri-
dized with 32P-labeled random primed human proMMP-1, proMMP-
3 or GAPDH cDNA in 50% (v/v) formamide/5xSSC/0.1% (w/v) 
SDS/1 X Denhardt's solution/50 mM Na3PO4/200 ug/ml of heat-dena-
tured salmon sperm DNA at 42°C for 18 h. After hybridization, the 
membrane was washed in lxSSC/0.1%o (w/v) SDS and washed in 
0.1XSSC/0.1% (w/v) SDS at room temperature for 30 min, respec-
tively, and then exposed to Konica X-ray film (Konica Co., Shinjuku, 
Tokyo, Japan) at -80°C. 
3. Results 
3.1. Suppression of the IL-la-induced production of 
proMMP-1 and proMMP-3 by UTI 
When confluent human uterine cervical fibroblasts were 
treated for 24 h with IL-la (1 ng/ml) which stimulates most 
connective tissue cells to produce proMMP-1 and proMMP-3 
[4,5] and participates in PROM [22,23] and uterine cervical 
ripening [24], the production of both proMMP-1 and 
proMMP-3 was augmented: about a 3-fold increase in immu-
noreactive respective enzyme was observed in the IL-la-
treated cells as compared to the control cells (Fig. 1). UTI 
effectively suppressed both basal and IL-la-augmented pro-
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Fig. 1. Effect of UTI on the production of proMMP-1, proMMP-3 
and TIMP-1 in human uterine cervical fibroblasts. Confluent human 
uterine cervical fibroblasts at the 6th passage were treated with IL-
l a (1 ng/ml) and/or UTI (0.32 |iM, 0.64 uM and 1.28 uM, respec-
tively) for 24 h. An aliquot (1 ml) of harvested culture media from 
triplicate wells was subjected to Western blot analysis to determine 
the proMMP-1, proMMP-3 and TIMP-1 as described in the text. 
The relative amounts of proMMP-1, proMMP-3 and TIMP-1 were 
quantified by densitometric scanning, taking the untreated cells as 
100%o. Three independent experiments using cells of different origins 
at different passages were highly reproducible, and typical data are 
shown. Lane 1, untreated cells; lanes 2-4, cells treated with UTI 
(0.32 uM, 0.64 u.M and 1.28 |xM, respectively); lane 5, cells treated 
with IL-la (1 ng/ml) and lanes 6-8, cells co-treated with IL-la (1 
ng/ml) and UTI (0.32 uM, 0.64 uM and 1.28 uM, respectively). 
duction of proMMP-1 and proMMP-3 in a dose-dependent 
manner (0.32-1.28 uM), and 1.28 uM UTI suppressed about 
40% of the IL-la-mediated production of both proMMP-1 
and proMMP-3. In addition, UTI more effectively suppressed 
the spontaneous production of these proMMPs whereas UTI 
only slightly suppressed the production of TIMP-1. These 
concentrations of UTI affected neither the thymidine incorpo-
ration into DNA (data not shown) nor the number of cells: 
when confluent cells were treated with UTI (0.32 u\M) and/or 
IL-la (1 ng/ml) for 24 h, the DNA content in control, UTI-, 
IL-la- and UTI plus IL-la-treated groups were 2.92 ±0.25, 
2.91 ±0.14, 3.02 ±0.24 and 2.97 ±0.27 (ug DNA/well; the 
mean ± S.D. for three wells), respectively, indicating that 
UTI specifically suppressed the production of proMMPs with-
out affecting the cell growth and/or cell functions. 
The effect of UTI on the production of proMMPs and 
TIMP-1 was also examined in human chorionic cells. As 
shown in Fig. 2, UTI suppressed the IL-la-augmented pro-
duction of proMMP-1 and both basal and IL-la-mediated 
production of proMMP-3 to a similar extent. Interestingly, 
more effective suppression (50% < ) of their production was 
observed even when cells were treated with 0.32 uM UTI. The 
production of TIMP-1 was also interfered by UTI to a lesser 
extent than that of proMMPs. We also confirmed that UTI 
did not reduce the total protein synthesis in human chorionic 
cells; when the confluent cells were treated with UTI (0.64 
uM) for 24 h and then co-incubated with [3H]amino acid 
mixture for the last 8 h, both control and UTI-treated cells 
uptook 2.33±0.22 and 2.35±0.12 (XlO"3 dpm/well; the 
mean ± S.D. for three wells) of 3H into protein fraction, re-
spectively. It therefore appears that UTI is an effective and 
selective suppressor of the production of proMMP-1, 
proMMP-3 and TIMP-1 not only in human uterine cervical 
fibroblasts, but also in human chorionic cells. 
K. Imada et allFEBS Letters 417 (1997) 337-340 339 
0 0 0 0 100 45 29 0 (%) 
100 31 21 5 420 260 158 23 (%) 
ProMMP-1 
ProMMP-3 
100 98 96 37 118 151 102 46 (%> 
TIMP-1 
1 8 
Fig. 2. Effect of UTI on the production of proMMP-1, proMMP-3 
and TIMP-1 in human chorionic cells. Confluent human chorionic 
cells at the 4th passage were treated with IL-la (1 ng/ml) and/or 
UTI (0.32 uM, 0.64 uM and 1.28 uM, respectively) for 24 h. An 
aliquot (1 ml) of harvested culture media from triplicate wells was 
subjected to Western blot analysis to detect the proMMP-1, 
proMMP-3 and TIMP-1 as described in the text. The relative 
amounts of proMMP-3 and TIMP-1 were quantified as described in 
Fig. 1. In the case of proMMP-1, the level of IL-la (lane 5) was 
taken as 100% because chorionic cells produced basically an insig-
nificant amount of the enzyme. Three independent experiments us-
ing cells of different origins at different passages were highly repro-
ducible, and typical data are shown. Lane 1, untreated cells; lanes 
2-4, cells treated with UTI (0.32 itM, 0.64 uM and 1.28 |xM, re-
spectively); lane 5, cells treated with IL-la (1 ng/ml) and lanes 6-8, 
cells co-treated with IL-la (1 ng/ml) and UTI (0.32 uM, 0.64 itM 
and 1.28 uM, respectively). 
3.2. UTI interferes the IL-la-induced accumulation of 
steady-state levels of MMP-1 and MMP-3 mRNAs 
Next, we examined whether the decrease in the proMMPs 
level caused by UTI resulted from the changes in their 
mRNAs. The changes in the steady-state levels of MMP-1 
and MMP-3 mRNAs were monitored by Northern blot anal-
ysis. Both non-treated uterine cervical fibroblasts and cho-
rionic cells contained slight MMP-1 and MMP-3 transcripts, 
and IL-la increased their transcripts obviously as shown in 
Fig. 3. UTI decreased the steady-state levels of MMP-1 and 
MMP-3 mRNAs in both cell species, whereas their suppres-
sion by UTI was less than that of protein levels. These results 
suggest that UTI controls the production of proMMP-1 and 
proMMP-3 in human uterine cervical cells and chorionic cells 
at both the transcriptional and post-transcriptional levels. 
4. Discussion 
Although UTI is well known as an inhibitor of serine pro-
teinases, recent reports that UTI suppresses the production of 
IL-8 in macrophages [13] and the lipopolysaccharide-induced 
Ca2+-influx into cells [25] are of great interest. These obser-
vations suggest that UTI exerts various functions on the cells. 
In this report, we demonstrated that UTI effectively sup-
presses the production of proMMP-1 and proMMP-3 accom-
panying the decrease in their mRNA expressions in human 
chorionic cells and in human uterine cervical fibroblasts. 
These suppressive effects were more remarkable in the former 
than in the latter. The reason why different actions of UTI 
were observed in these two cell species is still unclear. The 
presence of two types of UTI receptor has been demonstrated 
on the cell surface of some tumor cells and leukocytes [26]. 
UTI receptors of human uterine cervical fibroblasts and cho-
rionic cells have not been characterized, but the different ef-
fects of UTI on these two cell types might be dependent upon 
the different number of UTI receptors expressed. In our ex-
periments, the production of TIMP-1 was also suppressed by 
UTI in these cell species, but to a lesser extent than that of 
proMMP-1 and proMMP-3, indicating that UTI is very likely 
to totally prevent the destruction of extracellular matrix. 
UTI also suppressed the accumulation of steady-state levels 
of MMP-1 and MMP-3 mRNAs with a lesser extent than 
their protein levels, suggesting that UTI biphasically regulates 
their production at the transcriptional and post-transcription-
al levels, and that UTI modulates for the most part at the 
latter level. Further studies are needed to clarify this complex 
mechanism. 
A higher concentration (about 0.64 |^M) of UTI was found 
in the neonatal urine than in adult urine, and UTI contained 
in amniotic fluid is considered to be derived from fetal urine 
[15]. It is thought that UTI in the amniotic fluid interferes 
with the proteolytic activity and closely participates in the 
maintenance of functions of fetal membrane during pregnancy 
[15]. Pharmacological dose of UTI also prevents premature 
cervical ripening by inhibiting the recruitment of neutrophils 
and the activity of elastase [17]. Our observation that UTI 
interferes the production of proMMP-1 and proMMP-3 con-
tributes to understanding about the mechanism of protective 
effect of UTI against preterm cervical ripening and preterm 
PROM. In addition, it is very likely that UTI inhibits the 
activation of these proMMPs because their activation is prob-
ably accomplished by trypsin and plasmin [4] which are effec-
tively inhibited by UTI. By contrast, we have confirmed that 
UTI does not directly inhibit MMPs activities (data not 
shown). 
In conclusion, we have demonstrated for the first time that 
in human uterine cervical fibroblasts and chorionic cells UTI 
down-regulates the production of proMMP-1 and proMMP-3 
accompanying with the decrease in expression of their 
mRNAs, and therefore UTI is very likely to participate in 
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Fig. 3. Effect of UTI on the steady-state mRNA levels of MMP-1 
and MMP-3. Confluent human uterine cervical fibroblasts at the 
3rd passage and human chorionic cells at the 5th passage were 
treated with IL-la (1 ng/ml) and/or UTI (1.28 uM) for 24 h. Total 
RNA (10 u,g) was subjected to Northern blot analysis as described 
in the text. The relative amounts of respective mRNA were quanti-
fied by densitometric scanning, and normalized with that of 
GAPDH mRNA taking the untreated cells as 100%. Three inde-
pendent experiments using cells of different origins at different pas-
sages were highly reproducible, and typical data are shown. Lane 1, 
untreated cells; lane 2, cells treated with UTI (1.28 uM); lane 3, 
cells treated with IL-la (1 ng/ml) and lane 4, cells co-treated with 
IL-la (1 ng/ml) and UTI (1.28 uM). 
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the maintenance of uterine cervix and fetal membranes by 
overall prevention of matrix breakdown. 
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